Search - tctmd.com

Displaying 881 - 900 of 1768

Sort: Relevancy | Date

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

Presentation

Comparative Efficacy and Safety of Reperfusion Therapy With Fibrinolytic Agents in STEMI Patients

August 18, 2017

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

Todd Neale

August 18, 2017

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

News Daily News

Costs Up, Usage Down: Hospitals Curtailed Use of CV Meds When Prices Soared

Todd Neale

August 15, 2017

Presentation

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

August 14, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Presentation

Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With DES

August 07, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Presentation

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

August 04, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

Advertisement

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Evolocumab Not Cost-Effective at Current List Price

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Comparative Efficacy and Safety of Reperfusion Therapy With Fibrinolytic Agents in STEMI Patients

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

Costs Up, Usage Down: Hospitals Curtailed Use of CV Meds When Prices Soared

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With DES

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content